In a recent study, the SGLT2 inhibitor canagliflozin showed promise as an adjunct treatment for reducing hyperinsulinemia in horses with insulin dysregulation.
Medical management of hyperinsulinemia with SGLT2 inhibitors is indicated for some horses, but it should be combined with appropriate management changes.
Researchers aimed to identify the most useful physical examination, metabolic, and management factors to predict laminitis risk in nonlaminitic ponies.
